Brief: Acadia Pharmaceuticals Q4 EPS USD 0.28 Vs. IBES Estimate USD 0.3
27/02/2024 21:05
Feb 27 (Reuters) - Acadia Pharmaceuticals Q4 net income USD 45.797 million vs. IBES estimate USD 52.2 million. * Q4 operating expenses USD 196.097 million * Q4 pretax profit USD 39.703 million vs. IBES estimate USD 53.3 million * Q4 product sales USD 231.041 million vs. IBES estimate USD 223.8 million
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP